Biotinylated Human Integrin alpha V beta 6 (ITGAV&ITGB6) Heterodimer Protein, His,Avitag™&Tag Free (MALS verified)
分子别名（Synonym）
Integrin alpha V beta 6,ITGAV&ITGB6
表达区间及表达系统（Source）
Biotinylated Human ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free (IT6-H82E4) is expressed from human 293 cells (HEK293). It contains AA Phe 31 - Val 992 (ITGAV) & Gly 22 - Asn 707 (ITGB6) (Accession # NP_002201.1 (ITGAV) & AAI21179.1 (ITGB6)).
Predicted N-terminus: Phe 31 (ITGAV) & Gly 22 (ITGB6)
蛋白结构（Molecular Characterization）
Biotinylated Human ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free, produced by co-expression of ITGAV and ITGB6, has a calculated MW of 114.7 kDa (ITGAV) and 79.6 kDa (ITGB6). Subunit ITGAV is fused with an acidic tail at the C-terminus and followed by a polyhistidine tag and an Avi tag (Avitag™) and subunit ITGB6 contains no tag but a basic tail at the C-terminus. The predicted N-terminus is Phe 31 (ITGAV) & Gly 22 (ITGB6). The non-reducing (NR) protein migrates as 135-150 kDa (ITGAV) and 82-95 kDa (ITGB6) respectively due to glycosylation.
标记（Labeling）
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白标记度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
纯度（Purity）
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景介绍
整合素αVβ6是由β6亚基与αV亚基构成的异二聚体，可作为纤连蛋白（fibronectin）和肌腱蛋白（cytotactin）的受体，特异性识别配体中的R-G-D氨基酸序列。该整合素通过网格蛋白介导的内吞作用促进癌细胞侵袭，同时也是柯萨奇病毒A9型（coxsackievirus A9）、柯萨奇病毒B1型（coxsackievirus B1）及单纯疱疹病毒-1型（HHV-1）的入侵受体。此外，它能结合TGF-β潜伏相关肽（LAP），从大分子潜伏复合体中激活TGF-β1或TGF-β3，此激活过程需与LTBP-1及纤连蛋白相互作用，并被PAR-1增强。
关键字： Integrin αVβ6;整合素αVβ6;Integrin αVβ6蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。